{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:06:11Z","timestamp":1792706771427,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.esmoop.2026.108344","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:34:08Z","timestamp":1785414848000},"page":"108344","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-9901","authenticated-orcid":false,"given":"D.-Y.","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-178X","authenticated-orcid":false,"given":"I.","family":"\u0141ugowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Stroyakovskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-7224","authenticated-orcid":false,"given":"K.H.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Dumas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Penkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-4385","authenticated-orcid":false,"given":"A.","family":"Dechaphunkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.T.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Chewaskulyong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8710-1020","authenticated-orcid":false,"given":"C.","family":"Charonpongsuntorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2221-9818","authenticated-orcid":false,"given":"D.","family":"Doroshow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-Y.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-P.","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kuptsova-Clarkson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Michelini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Puvvada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.esmoop.2026.108344_bib3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.annonc.2023.08.005","article-title":"HER2-low expression in patients with advanced or metastatic solid tumors","volume":"34","author":"Uzunparmak","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108344_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2020.08.006","article-title":"Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer","volume":"105","author":"Hiraoka","year":"2020","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108344_bib5","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1634\/theoncologist.2019-0922","article-title":"HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer","volume":"25","author":"Vivaldi","year":"2020","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108344_bib6","first-page":"42","article-title":"Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer","volume":"7","author":"Roa","year":"2014","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.esmoop.2026.108344_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/gm482","article-title":"Clinical and molecular characterization of HER2 amplified-pancreatic cancer","volume":"5","author":"Chou","year":"2013","journal-title":"Genome Med"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108344_bib8","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/diagnostics11040653","article-title":"The prognostic impact of HER2 genetic and protein expression in pancreatic carcinoma-HER2 protein and gene in pancreatic cancer","volume":"11","author":"Han","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108344_bib9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"issue":"20","key":"10.1016\/j.esmoop.2026.108344_bib10","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108344_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108344_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nrc.2016.35","article-title":"Defining actionable mutations for oncology therapeutic development","volume":"16","author":"Carr","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108344_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"ESMO clinical practice guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108344_bib18","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.108344_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104528","article-title":"ESMO clinical practice guideline express update on the management of metastatic pancreatic cancer","volume":"10","author":"Conroy","year":"2025","journal-title":"ESMO Open"},{"issue":"10409","key":"10.1016\/j.esmoop.2026.108344_bib20","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108344_bib21","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1007\/s12325-024-02975-x","article-title":"Efficacy of trastuzumab deruxtecan in HER2 expressing solid tumors by enrollment HER2 IHC status: post hoc analysis of DESTINY PanTumor02","volume":"41","author":"Oaknin","year":"2024","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108344_bib22","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108344_bib23","volume":"35","author":"Ikeda","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108344_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-031621-024600","article-title":"Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance","volume":"18","author":"Sherman","year":"2023","journal-title":"Annu Rev Pathol"},{"issue":"15","key":"10.1016\/j.esmoop.2026.108344_bib25","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1158\/1078-0432.CCR-14-1051","article-title":"Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer","volume":"21","author":"Whatcott","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108344_bib26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108344_bib27","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","volume":"20","author":"Shitara","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108344_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105306","article-title":"Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers","volume":"10","author":"Iida","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108344_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41698-024-00505-0","article-title":"Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma","volume":"8","author":"Yousef","year":"2024","journal-title":"NPJ Precis Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108344_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53039-y","article-title":"Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients","volume":"9","author":"Dong","year":"2019","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108344_bib31","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s12094-025-03887-0","article-title":"HER2-targeted therapy in colorectal cancer: a comprehensive review","volume":"27","author":"Benli","year":"2025","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108344_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2016.18","article-title":"KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma","volume":"7","author":"Bournet","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108344_bib33","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-24-3149","article-title":"Distinct molecular and clinical features of specific variants of KRAS codon 12 in pancreatic adenocarcinoma","volume":"31","author":"Ardalan","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"27","key":"10.1016\/j.esmoop.2026.108344_bib34","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2\u2013expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","volume":"42","author":"Ohba","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108344_bib35","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108344_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoncol.2025.4736","article-title":"Zanidatamab in HER2-positive metastatic biliary tract cancer: final results from HERIZON-BTC-01","volume":"12","author":"Pant","year":"2026","journal-title":"JAMA Oncol"},{"issue":"36","key":"10.1016\/j.esmoop.2026.108344_bib39","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.1200\/JCO.23.00606","article-title":"Tucatinib and trastuzumab for previously treated human epidermal growth factor receptor 2\u2013positive metastatic biliary tract cancer (SGNTUC-019): a phase II basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108344_bib40","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108344_bib41","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/bjc.2012.18","article-title":"Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer","volume":"106","author":"Harder","year":"2012","journal-title":"Br J Cancer"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2026.108344_bib42","article-title":"400TiP An open-label, multicenter, phase II study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) part 2","volume":"35","author":"Lee","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108344_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis \u2013 focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2026.108344_bib44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.breast.2023.06.005","article-title":"Concordance of HER2-low scoring in breast carcinoma among expert pathologists in the United Kingdom and the Republic of Ireland \u2013 on behalf of the UK national coordinating committee for breast pathology","volume":"70","author":"Zaakouk","year":"2023","journal-title":"Breast"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108344_bib45","first-page":"704","article-title":"Utilization of HER2 genetic testing in a multi-institutional observational study","volume":"18","author":"Goddard","year":"2012","journal-title":"Am J Manag Care"},{"issue":"10","key":"10.1016\/j.esmoop.2026.108344_bib46","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.5858\/arpa.2022-0229-CP","article-title":"Current laboratory testing practices for assessment of ERBB2\/HER2 in endometrial serous carcinoma and colorectal carcinoma","volume":"147","author":"Hagemann","year":"2023","journal-title":"Arch Pathol Lab Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926022866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:33:09Z","timestamp":1787848389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926022866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2059702926022866"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108344","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108344","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108344"}}